RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
Abstract Background Cancer immunotherapy has transformed metastatic cancer treatment, yet challenges persist regarding therapeutic efficacy. RECQL4, a RecQ‐like helicase, plays a central role in DNA replication and repair as part of the DNA damage response, a pathway implicated in enhancing efficacy...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
Wiley
2025-01-01
|
| Schriftenreihe: | Clinical and Translational Medicine |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1002/ctm2.70094 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|